Director Richard Peter Marshall bought 12,183 shares at $1.65 in first transaction; stock down 75.0% from 52-week high of $7.92
Director Richard Peter Marshall acquired 12,183 shares at $1.65 on 2026-05-19, representing his first open-market purchase at Serina Therapeutics. The transaction occurs after the stock has declined 75.0% from its 52-week high of $7.92, placing it near the low end of the 52-week range of $1.22–$7.92. The company remains unprofitable with net income of $-6,898,000.00 and zero revenue in the latest quarter, though it reported annual revenue growth of +132.1% year-over-year. The purchase warrants examination of whether it reflects conviction in a turnaround narrative or is simply opportunistic positioning at depressed levels in a cash-burning enterprise.